Future perspectives on mesenchymal stromal cell-derived secretomes in knee osteoarthritis

Table 2 Critical challenges in mesenchymal stromal cell-derived secretome translation and proposed solutions

Challenge category	Specific issues	Current status	Proposed solutions	Timeline to resolution
Product standardization
Source MSC variability	Donor age, tissue source, comorbidities affect secretome	Widely recognized; limited consensus	Establish standardized donor selection criteria; focus on allogeneic young, healthy donors; develop potency-based lot selection	2-3 years
Isolation method heterogeneity	Multiple protocols yield different products	MISEV guidelines provide research framework	Develop GMP-compliant isolation protocols; comparative studies of methods vs clinical outcomes	3-5 years
Batch-to-batch consistency	Manufacturing variability affects reproducibility	Early-stage optimization in progress	Implement process analytical technology; establish critical quality attributes	3-5 years
Quality control
Potency assay development	Lack of validated functional assays	Multiple candidate assays under evaluation	Validate multi-parameter potency testing; correlate with clinical outcomes	4-6 years
Characterization complexity	Thousands of components; incomplete understanding of active elements	Improving with advanced analytics	Employ systems biology approaches; identify critical therapeutic components	5-7 years
Stability testing	Degradation kinetics poorly defined	Limited systematic data	Conduct comprehensive stability studies across formulations; develop real-time potency monitoring	2-4 years
Delivery optimization
Rapid intra-articular clearance	Limits sustained therapeutic effect	Well-documented in preclinical models	Develop sustained-release formulations; explore biomaterial carriers; optimize injection timing	3-5 years
Limited cartilage penetration	Chondrocyte targeting inefficient	Recognized challenge; solutions in early development	Engineer targeting moieties; optimize EV size for matrix penetration	4-6 years
Dosing regimen uncertainty	Single vs multiple injections; optimal intervals unknown	Clinical trials using variable regimens	Conduct systematic dose-finding and dose-timing studies	5-7 years
Clinical validation
Lack of phase III data	Efficacy vs placebo unproven	Phase I/II ongoing; phase III planning	Execute large, adequately powered RCTs with appropriate controls	5-8 years
Patient selection optimization	Ideal disease stage and phenotype undefined	Exploratory analyses in early trials	Develop predictive biomarkers; conduct stratified analyses	4-6 years
Outcome measure sensitivity	Traditional outcomes require large N and long duration	Alternative outcomes under evaluation	Validate imaging and biochemical biomarkers; incorporate patient-reported outcomes	3-5 years
Regulatory challenges
Classification ambiguity	Unclear regulatory pathway	Ongoing agency discussions	Establish precedent through lead product approvals; develop guidance documents	3-5 years
Manufacturing requirements	GMP standards incompletely defined for secretomes	Evolving with agency feedback	Develop industry consensus standards; leverage existing biologic manufacturing frameworks	3-5 years
Economic challenges
Reimbursement pathway	Unclear payer coverage for novel biologic	No established codes or reimbursement	Demonstrate cost-effectiveness vs current care; establish value-based pricing	5-10 years
Manufacturing economics	Production costs potentially prohibitive	Economies of scale not yet achieved	Optimize yields; develop scalable processes; explore biosimilar pathways post-approval	5-7 years

MSC: Mesenchymal stromal cell; GMP: Good manufacturing practice; MISEV: Minimal Information for Studies of Extracellular Vesicles; EV: Extracellular vesicle.